Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

OXBRYTA Medication Guide (voxelotor)

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Hypersensitivity Reactions

Advise patients that serious hypersensitivity reactions may occur, and to notify their healthcare providers if they develop generalized rash, urticaria, shortness of breath, facial swelling and eosinophilia [see Warnings and Precautions (5.1)].

Breastfeeding

Advise women not to breastfeed while they are on OXBRYTA therapy [see Use in Specific Populations (8.2)].

Dosage and Administration

To avoid a dosing error from using the wrong formulation of OXBRYTA, strongly advise patients and caregivers to visually inspect the tablets to verify the correct formulation each time the prescription is filled [see Dosage and Administration (2) and How Supplied/Storage and Handling (16)].

Advise patients to:

  • Store OXBRYTA at 20°C to 30°C (68°F to 86°F).
  • Continue taking OXBRYTA every day for as long as their physician tells them.
  • Do not take St John's wort while taking OXBRYTA.
  • Swallow OXBRYTA tablets whole. Do not cut, crush, or chew the tablets.
  • Do not swallow whole, cut, crush, or chew OXBRYTA tablets for oral suspension. Disperse OXBRYTA tablets for oral suspension in room temperature clear drink (such as drinking water, clear soda, apple juice, clear electrolyte drinks, clear flavored drinks, or clear sports drinks) before administration. The amount of liquid needed to disperse the tablets for oral suspension will depend on the dose (number of tablets prescribed) [see Dosage and Administration (2.7)].
  • Take OXBRYTA with or without food.
  • If a dose is missed or not consumed entirely, resume dosing the following day [see Dosage and Administration (2.7)].

PATIENT INFORMATION
OXBRYTA® (ox brye ta)
(voxelotor)
tablets		 OXBRYTA® (ox brye ta)
(voxelotor)
tablets for oral suspension
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 10/2022    
What is OXBRYTA?
OXBRYTA is a prescription medicine used for the treatment of sickle cell disease in adults and children 4 years of age and older.
It is not known if OXBRYTA is safe and effective in children with sickle cell disease below 4 years of age.
Do not take OXBRYTA if you or your child have had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of this leaflet for a list of the ingredients in OXBRYTA.
Before taking OXBRYTA, tell your healthcare provider about all of your medical conditions, including if you or your child:
  • have liver problems
  • are pregnant or plan to become pregnant. It is not known if OXBRYTA can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if OXBRYTA can pass into your breastmilk and if it can harm your baby. Do not breastfeed during treatment with OXBRYTA and for at least 2 weeks after the last dose.
Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how OXBRYTA works. OXBRYTA may also affect how other medicines work and may affect the results of certain blood tests. Keep a list of all your medicines and show it to your healthcare provider.
How should I take OXBRYTA?
  • Take OXBRYTA exactly as your healthcare provider tells you.
  • Do not change your dose or stop taking OXBRYTA unless your healthcare provider tells you to. Your healthcare provider may change your dose if needed.
  • Take your prescribed dose of OXBRYTA 1 time each day.
  • Take OXBRYTA with or without food.
  • OXBRYTA comes in two different dosage forms, OXBRYTA tablets and OXBRYTA tablets for oral suspension. Your healthcare provider will decide which dosage form you take based on your age, weight, and ability to swallow tablets.
    • If you take OXBRYTA tablets: Swallow each OXBRYTA tablet whole. Do not cut, crush, or chew the tablets.
    • If you take OXBRYTA tablets for oral suspension: See the detailed Instructions for Use on how to prepare and take your dose. You must mix the OXBRYTA tablets for oral suspension in room temperature clear drink, such as drinking water, clear soda, apple juice, clear electrolyte drinks, clear flavored drinks, or clear sports drinks, right before taking it. Do not swallow whole, cut, crush, or chew the tablets for oral suspension.
  • Check to make sure you receive the correct dosage form of OXBRYTA each time your prescription is filled to avoid taking the wrong medicine.
  • Your healthcare provider may also prescribe a medicine called hydroxyurea during treatment with OXBRYTA.
  • If you or your child miss a dose of OXBRYTA or if the entire dose is not taken, skip that dose and return to your normal dosing schedule the next day.
What should I avoid while taking OXBRYTA?
Do not take St. John's wort during treatment with OXBRYTA.
What are the possible side effects of OXBRYTA?
OXBRYTA can cause serious side effects, including:
  • Serious allergic reactions. Tell your healthcare provider or get emergency medical help right away if you get:
  • rash
  • hives
  • shortness of breath (difficult breathing)
  • swelling of the face
The most common side effects of OXBRYTA include:
  • headache
  • diarrhea
  • stomach-area (abdominal) pain
  • nausea
  • rash or hives
  • fever
The most common side effects of OXBRYTA in children ages 4 to less than 12 years of age include:
  • fever
  • vomiting
  • rash
  • stomach-area (abdominal) pain
  • diarrhea
  • headache
These are not all the possible side effects of OXBRYTA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
You may also report side effects to Global Blood Therapeutics, Inc. at 1-833-428-4968 (1-833-GBT-4YOU).
How should I store OXBRYTA?
  • Store OXBRYTA between 68°F to 86°F (20°C to 30°C).
  • The OXBRYTA bottle comes with a child-resistant closure.
  • The OXBRYTA bottle may contain a desiccant canister to help keep your medicine dry (protect it from moisture) and a polyester coil. Do not eat the desiccant or polyester coil.
Keep OXBRYTA and all medicines out of the reach of children.
General information about the safe and effective use of OXBRYTA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use OXBRYTA for a condition for which it was not prescribed. Do not give OXBRYTA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about OXBRYTA that is written for health professionals.
What are the ingredients of OXBRYTA?
Active Ingredient: voxelotor
Inactive Ingredients:
OXBRYTA tablets: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The 500 mg tablet film coating contains: polyethylene glycol 3350, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide. The 300 mg tablet film coating contains: black and red iron oxide, polyethylene glycol 3350, polyvinyl alcohol, talc, and titanium dioxide.
OXBRYTA tablets for oral suspension: artificial grape flavor, colloidal silicon dioxide, croscarmellose sodium, iron oxide pigment, magnesium stearate, microcrystalline cellulose, and sucralose.

Manufactured for: Global Blood Therapeutics, Inc. South San Francisco, CA 94080, USA.
OXBRYTA®
© 2022 Global Blood Therapeutics, Inc. All rights reserved. For more information, call 1-833-428-4968 (1-833-GBT-4YOU) or go to www.OXBRYTA.com.
Show All Hide All
Show All Hide All
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event
Pfizer Safety

To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at
(800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatchor by calling
(800)-332-1088.